Studies pregnancy and infant outcomes after deucravacitinib in people with psoriasis
Follows pregnant people with psoriasis who took deucravacitinib, tracking pregnancy and infant outcomes.
Plain-language title generated from the registry record
Registry title: A Study to Assess Deucravacitinib Safety in Pregnancy
Key facts
- Where
- La Jolla, United StatesSee the site
Where in United States
- University of California San DiegoLa Jolla, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07017699
- Record updated
- 1 October 2026
- Original description
The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists [OTIS]) who were exposed to deucravacitinib.Read full original descriptionShow less
The Deucravacitinib Pregnancy Exposure Study: A Prospective Observational Study of Deucravacitinib Safety in Pregnancy
The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists [OTIS]) who were exposed to deucravacitinib.
Inclusion: Cohort 1: Deucravacitinib-exposed cohort; Currently pregnant during the enrollment period; Diagnosed with psoriasis (PsO) validated by medical records when possible; Exposure to deucravacitinib for any number of days, at any dose, and at any time from 2 days prior to date of conception (DOC) to the end of pregnancy; Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants; Cohort 2: PsO Disease-matched unexposed comparator cohort; Currently pregnant during the enrollment period; Diagnosed with PsO validated by medical records when possible; May be exposed to systemic treatments for PsO; Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants; Cohort 3: Non-disease unexposed comparator cohort; Currently pregnant during the enrollment period; Agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the dysmorphology examination of live born infants.
Exclusion: Pregnant women who have enrolled in this cohort study with a previous pregnancy; Women who do not have exposure to deucravacitinib anytime from 2 days prior to DOC to the end of pregnancy; Women who have exposure to another oral tyrosine kinase 2 (TYK2) inhibitor or any oral Janus kinase (JAK) inhibitor from within 5 half-lives of DOC to the end of pregnancy; Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment); Results of a diagnostic test are positive for an major congenital malformation(s) (MCM) prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM; Cohort 2: Disease-matched unexposed comparator cohort; Pregnant women who have enrolled in this cohort study with a previous pregnancy; Women who have exposure to deucravacitinib or any other oral TYK2 inhibitor except deucravacitinib, or any oral JAK inhibitor from within 5 half-lives of DOC to the end of pregnancy; Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment); Results of a diagnostic test are positive for an MCM prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM; Cohort 3: Non-disease unexposed comparator cohort; Pregnant women who have enrolled in this cohort study with a previous pregnancy; Women who have had exposure to deucravacitinib or any other oral TYK2 inhibitor, or any oral JAK inhibitor from within 5 half-lives of DOC to the end of pregnancy; Retrospective enrollment after the outcome of pregnancy is known (ie, the pregnancy has ended prior to enrollment); Results of a diagnostic test are positive for an MCM prior to enrollment. However, women who have had any normal or abnormal prenatal screening or diagnostic test prior to enrollment are eligible as long as the test result does not indicate an MCM; Women who are diagnosed with PsO, or any other autoimmune disease; Cohort 1: Deucravacitinib-exposed cohort; Pregnant women who have used deucravacitinib for an indication other than PsO; Women who have exposure to methotrexate or an oral retinoid; Women who have exposure to methotrexate or an oral retinoid; Women exposed to a known, possible, or suspected human teratogen during pregnancy as confirmed by the OTIS Research Center (see Appendix 3 for list of known, possible, and suspected human teratogens).